Clinical Trial Update: A Dose Ranging Study to Examine TDS-Testosterone 5% [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of TDS-Testosterone 5% for hypogonadotropism is described; recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropism

Drugs mentioned

• TDS-Testosterone 5%

Snippet

Sponsor: Transdermal Delivery Solutions Corp | Conditions: Hypogonadotropism | Phase 2 | Status: NOT_YET_RECRUITING